Details

Autor(en) / Beteiligte

• van Bodegraven, Mirja
• Kröger, Marius
• Zamudio Díaz, Daniela F.
• Lohan, Silke B.
• Moritz, Rose K. C.
• Möller, Nadine
• Knoblich, Chiara
• Vogelsang, Alexandra
• Milinic, Zorica
• Hallhuber, Matthias
• Weise, Julia M.
• Kolbe, Ludger
• Gallinger, Julia
• Graupner, Cindy
• Klose, Holger
• Ulrich, Claas
• Meinke, Martina C.

Titel

Redefine photoprotection: Sun protection beyond sunburn

Ist Teil von

• Experimental dermatology, 2024-01, Vol.33 (1), p.e15002-n/a

Ort / Verlag

Denmark: Wiley Subscription Services, Inc

Erscheinungsjahr

2024

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Excessive exposure to ultraviolet (UV) light leads to acute and chronic UV damage and is the main risk factor for the development of skin cancer. In most countries with western lifestyle, the topical application of sunscreens on UV‐exposed skin areas is by far the most frequently used preventive measure against sunburn. Further than preventing sunburns, increasing numbers of consumers are appreciating sunscreens with a medium‐ to high‐level sun protective factor (SPF) as basis for sustainable‐skin ageing or skin cancer prevention programs. However, recent investigations indicate that clinically significant DNA damages as well as a lasting impairment of cutaneous immunosurveillance already occur far below the standard of one minimal erythema dose (MED) sunburn level, which contributes to the current discussion of the clinical value of high‐protective SPF values. Ex vivo investigations on human skin showed that the application of SPF30 reduces DNA damage for a day long sun exposure (24 MED) drastically by about 53% but is significantly surpassed by SPF100 reducing DNA damage by approx. 73%. Further analysis on different SPF protection levels in UV‐exposed cell culture assays focusing on IL‐18, cell vitality and cis/trans‐urocanic acid support these findings. Whereas SPF30 and SPF50+ sunscreens already offer a solid UVB cover for most indications, our results indicate that SPF100 provides significant additional protection against mutagenic (non‐apoptotic‐) DNA damage and functional impairment of the cutaneous immunosurveillance and therefore qualifies as an optimized sunscreen for specifically vulnerable patient groups such as immunosuppressed patients, or skin cancer patients. The application of a sunscreen with SPF100 protects the skin significantly better against skin damage by altering the inflammation marker IL‐18, cell vitality, cis‐UCA levels and DNA damage compared to SPF30 and SPF50+ by up to 40%.